The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Kidney Disease (CKD) Drugs Market Research Report 2024
Synopsis
Chronic Kidney Disease (CKD) Drugs are drugs for Chronic kidney disease, which also called chronic kidney failure, describes the gradual loss of kidney function.
The global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 13990 million in 2023 and is anticipated to reach US$ 15730 million by 2030, witnessing a CAGR of 1.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. The hospitals segment, which is the current market leader, is expected to continue its dominance in this market over the next few years.
This report aims to provide a comprehensive presentation of the global market for Chronic Kidney Disease (CKD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Kidney Disease (CKD) Drugs.
Report Scope
The Chronic Kidney Disease (CKD) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Kidney Disease (CKD) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Kidney Disease (CKD) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer, Inc.
Amgen
Roche
GlaxoSmithKline (GSK)
Allergan
AbbVie
Kissei Pharmaceutical Co., Ltd.
Segment by Type
ACE Inhibitors
Angiotensin-II Receptor Blockers
Calcium Channel Blockers
Beta Blockers: BREVIBLOC, Bystolic
Others
Segment by Application
Hospitals
Specialty Clinics
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Kidney Disease (CKD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Kidney Disease (CKD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Chronic Kidney Disease (CKD) Drugs are drugs for Chronic kidney disease, which also called chronic kidney failure, describes the gradual loss of kidney function.
The global Chronic Kidney Disease (CKD) Drugs market was valued at US$ 13990 million in 2023 and is anticipated to reach US$ 15730 million by 2030, witnessing a CAGR of 1.7% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs. The hospitals segment, which is the current market leader, is expected to continue its dominance in this market over the next few years.
This report aims to provide a comprehensive presentation of the global market for Chronic Kidney Disease (CKD) Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Chronic Kidney Disease (CKD) Drugs.
Report Scope
The Chronic Kidney Disease (CKD) Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Chronic Kidney Disease (CKD) Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Chronic Kidney Disease (CKD) Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Pfizer, Inc.
Amgen
Roche
GlaxoSmithKline (GSK)
Allergan
AbbVie
Kissei Pharmaceutical Co., Ltd.
Segment by Type
ACE Inhibitors
Angiotensin-II Receptor Blockers
Calcium Channel Blockers
Beta Blockers: BREVIBLOC, Bystolic
Others
Segment by Application
Hospitals
Specialty Clinics
Consumption by Region
North America
United States
Canada
Mexico
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Chronic Kidney Disease (CKD) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Chronic Kidney Disease (CKD) Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Chronic Kidney Disease (CKD) Drugs Market Overview
1.1 Product Overview and Scope of Chronic Kidney Disease (CKD) Drugs
1.2 Chronic Kidney Disease (CKD) Drugs Segment by Type
1.2.1 Global Chronic Kidney Disease (CKD) Drugs Market Value Comparison by Type (2024-2030)
1.2.2 ACE Inhibitors
1.2.3 Angiotensin-II Receptor Blockers
1.2.4 Calcium Channel Blockers
1.2.5 Beta Blockers: BREVIBLOC, Bystolic
1.2.6 Others
1.3 Chronic Kidney Disease (CKD) Drugs Segment by Application
1.3.1 Global Chronic Kidney Disease (CKD) Drugs Market Value by Application: (2024-2030)
1.3.2 Hospitals
1.3.3 Specialty Clinics
1.4 Global Chronic Kidney Disease (CKD) Drugs Market Size Estimates and Forecasts
1.4.1 Global Chronic Kidney Disease (CKD) Drugs Revenue 2019-2030
1.4.2 Global Chronic Kidney Disease (CKD) Drugs Sales 2019-2030
1.4.3 Global Chronic Kidney Disease (CKD) Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Chronic Kidney Disease (CKD) Drugs Market Competition by Manufacturers
2.1 Global Chronic Kidney Disease (CKD) Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Chronic Kidney Disease (CKD) Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Chronic Kidney Disease (CKD) Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Chronic Kidney Disease (CKD) Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Chronic Kidney Disease (CKD) Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Chronic Kidney Disease (CKD) Drugs, Product Type & Application
2.7 Chronic Kidney Disease (CKD) Drugs Market Competitive Situation and Trends
2.7.1 Chronic Kidney Disease (CKD) Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Chronic Kidney Disease (CKD) Drugs Players Market Share by Revenue
2.7.3 Global Chronic Kidney Disease (CKD) Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Chronic Kidney Disease (CKD) Drugs Retrospective Market Scenario by Region
3.1 Global Chronic Kidney Disease (CKD) Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Chronic Kidney Disease (CKD) Drugs Global Chronic Kidney Disease (CKD) Drugs Sales by Region: 2019-2030
3.2.1 Global Chronic Kidney Disease (CKD) Drugs Sales by Region: 2019-2024
3.2.2 Global Chronic Kidney Disease (CKD) Drugs Sales by Region: 2025-2030
3.3 Global Chronic Kidney Disease (CKD) Drugs Global Chronic Kidney Disease (CKD) Drugs Revenue by Region: 2019-2030
3.3.1 Global Chronic Kidney Disease (CKD) Drugs Revenue by Region: 2019-2024
3.3.2 Global Chronic Kidney Disease (CKD) Drugs Revenue by Region: 2025-2030
3.4 North America Chronic Kidney Disease (CKD) Drugs Market Facts & Figures by Country
3.4.1 North America Chronic Kidney Disease (CKD) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Chronic Kidney Disease (CKD) Drugs Sales by Country (2019-2030)
3.4.3 North America Chronic Kidney Disease (CKD) Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.4.6 Mexico
3.5 Europe Chronic Kidney Disease (CKD) Drugs Market Facts & Figures by Country
3.5.1 Europe Chronic Kidney Disease (CKD) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Chronic Kidney Disease (CKD) Drugs Sales by Country (2019-2030)
3.5.3 Europe Chronic Kidney Disease (CKD) Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 UK
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Chronic Kidney Disease (CKD) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Chronic Kidney Disease (CKD) Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Chronic Kidney Disease (CKD) Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Indonesia
3.6.10 Thailand
3.6.11 Malaysia
3.6.12 Philippines
3.6.13 Vietnam
3.7 Latin America Chronic Kidney Disease (CKD) Drugs Market Facts & Figures by Country
3.7.1 Latin America Chronic Kidney Disease (CKD) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Chronic Kidney Disease (CKD) Drugs Sales by Country (2019-2030)
3.7.3 Latin America Chronic Kidney Disease (CKD) Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Chronic Kidney Disease (CKD) Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Chronic Kidney Disease (CKD) Drugs Sales by Type (2019-2030)
4.1.1 Global Chronic Kidney Disease (CKD) Drugs Sales by Type (2019-2024)
4.1.2 Global Chronic Kidney Disease (CKD) Drugs Sales by Type (2025-2030)
4.1.3 Global Chronic Kidney Disease (CKD) Drugs Sales Market Share by Type (2019-2030)
4.2 Global Chronic Kidney Disease (CKD) Drugs Revenue by Type (2019-2030)
4.2.1 Global Chronic Kidney Disease (CKD) Drugs Revenue by Type (2019-2024)
4.2.2 Global Chronic Kidney Disease (CKD) Drugs Revenue by Type (2025-2030)
4.2.3 Global Chronic Kidney Disease (CKD) Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Chronic Kidney Disease (CKD) Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Chronic Kidney Disease (CKD) Drugs Sales by Application (2019-2030)
5.1.1 Global Chronic Kidney Disease (CKD) Drugs Sales by Application (2019-2024)
5.1.2 Global Chronic Kidney Disease (CKD) Drugs Sales by Application (2025-2030)
5.1.3 Global Chronic Kidney Disease (CKD) Drugs Sales Market Share by Application (2019-2030)
5.2 Global Chronic Kidney Disease (CKD) Drugs Revenue by Application (2019-2030)
5.2.1 Global Chronic Kidney Disease (CKD) Drugs Revenue by Application (2019-2024)
5.2.2 Global Chronic Kidney Disease (CKD) Drugs Revenue by Application (2025-2030)
5.2.3 Global Chronic Kidney Disease (CKD) Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Chronic Kidney Disease (CKD) Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Pfizer, Inc.
6.1.1 Pfizer, Inc. Corporation Information
6.1.2 Pfizer, Inc. Description and Business Overview
6.1.3 Pfizer, Inc. Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Pfizer, Inc. Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.1.5 Pfizer, Inc. Recent Developments/Updates
6.2 Amgen
6.2.1 Amgen Corporation Information
6.2.2 Amgen Description and Business Overview
6.2.3 Amgen Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Amgen Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.2.5 Amgen Recent Developments/Updates
6.3 Roche
6.3.1 Roche Corporation Information
6.3.2 Roche Description and Business Overview
6.3.3 Roche Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Roche Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.3.5 Roche Recent Developments/Updates
6.4 GlaxoSmithKline (GSK)
6.4.1 GlaxoSmithKline (GSK) Corporation Information
6.4.2 GlaxoSmithKline (GSK) Description and Business Overview
6.4.3 GlaxoSmithKline (GSK) Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 GlaxoSmithKline (GSK) Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.4.5 GlaxoSmithKline (GSK) Recent Developments/Updates
6.5 Allergan
6.5.1 Allergan Corporation Information
6.5.2 Allergan Description and Business Overview
6.5.3 Allergan Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Allergan Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.5.5 Allergan Recent Developments/Updates
6.6 AbbVie
6.6.1 AbbVie Corporation Information
6.6.2 AbbVie Description and Business Overview
6.6.3 AbbVie Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 AbbVie Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.6.5 AbbVie Recent Developments/Updates
6.7 Kissei Pharmaceutical Co., Ltd.
6.6.1 Kissei Pharmaceutical Co., Ltd. Corporation Information
6.6.2 Kissei Pharmaceutical Co., Ltd. Description and Business Overview
6.6.3 Kissei Pharmaceutical Co., Ltd. Chronic Kidney Disease (CKD) Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Kissei Pharmaceutical Co., Ltd. Chronic Kidney Disease (CKD) Drugs Product Portfolio
6.7.5 Kissei Pharmaceutical Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Chronic Kidney Disease (CKD) Drugs Industry Chain Analysis
7.2 Chronic Kidney Disease (CKD) Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Chronic Kidney Disease (CKD) Drugs Production Mode & Process
7.4 Chronic Kidney Disease (CKD) Drugs Sales and Marketing
7.4.1 Chronic Kidney Disease (CKD) Drugs Sales Channels
7.4.2 Chronic Kidney Disease (CKD) Drugs Distributors
7.5 Chronic Kidney Disease (CKD) Drugs Customers
8 Chronic Kidney Disease (CKD) Drugs Market Dynamics
8.1 Chronic Kidney Disease (CKD) Drugs Industry Trends
8.2 Chronic Kidney Disease (CKD) Drugs Market Drivers
8.3 Chronic Kidney Disease (CKD) Drugs Market Challenges
8.4 Chronic Kidney Disease (CKD) Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
